VTE PROPHYLAXIS NOW RECOMMENDED FOR CANCER PATIENTS
The National Comprehensive CancerNetwork (NCCN) recently issued guidelinesrecommending inpatient prophylacticanticoagulation therapy withunfractionated heparin, low-molecularweightheparin (LMWH), or fondaparinux.The guidelines do not address outpatientprophylaxis, but they suggestimmediate and long-term treatmentonce an episode of venous thromboembolism(VTE) occurs. The NCCN recommends3 to 6 months of treatment fordeep vein thrombosis, 6 to 12 months oftreatment for pulmonary embolism, andindefinite treatment for patients withactive cancer or persistent risk factors.
The NCCN recommends the use ofLMWH or warfarin for long-term treatmentand secondary prevention. Preliminarydata suggest an improved survivalbenefit using LMWH, however. Thenew guidelines may be accessed atwww.nccn.org/professionals/physician_gls/sPDF/vte.pdf.
Dr. Garrett is a clinical pharmacistpractitioner at Cornerstone Health Carein High Point, NC.
Articles in this issue
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
- Evaluation of Pharmacist-Driven Penicillin Allergy Reconciliation
September 17th 2025
- Pharmacists Can Apply Their Expertise to the Medical Psilocybin Act
September 16th 2025
- From Curiosity to Clinical Impact: Shremo Msdi’s Path in Pharmacy Research
September 15th 2025